8 recruiting, 6 active not recruiting, 2 completed, 2 not yet recruiting. 22 Phase 2, 3 Phase 3, 2 Phase 1.
Follow entrectinib: new trials by email Literature Review of entrectinib trials Research Report on entrectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma Alectinib, Entrectinib, Surgery - Infant-Type Hemispheric Glioma | Phase 2 | Not yet recruiting | St. Jude Children's Research Hospital | 50 | 2026-11-01 | 2026-11-04 |
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Entrectinib, Cyclophosphamide, Etoposide - High Grade Glioma, CNS Tumor | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 52 | 2026-05-01 | 2026-11-03 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2026-11-10 |
| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer Anlotinib, Lenvatinib, Sorafenib - Locally Advanced Thyroid Gland Carcinoma | Phase 2 | Recruiting | West China Hospital | 75 | 2021-06-01 | 2024-12-05 |
| Improving Public Cancer Care by Implementing Precision Medicine in Norway Atezolizumab - Cancer Metastatic | Phase 2 | Recruiting | Oslo University Hospital | 3000 | 2021-04-01 | 2024-02-29 |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Entrectinib, Alectinib, Atezolizumab - Solid Tumors | Phase 2 | Active not recruiting | Hoffmann-La Roche | 920 | 2021-01-18 | 2026-09-04 |
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) Entrectinib, Letrozole, Goserelin - Invasive Lobular Breast Carcinoma, ER+ Breast Cancer | Phase 2 | Unknown | Jules Bordet Institute | 65 | 2021-01-14 | 2024-12-04 |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Entrectinib, Inavolisib, Alectinib - Advanced Unresectable or Metastatic Solid Malignancy | Phase 2 | Completed | Genentech, Inc. | 252 | 2021-01-13 | 2025-01-08 |
| Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma PAC-1, Entrectinib - Uveal Melanoma | Phase 1 / Phase 2 | Terminated | Arkadiusz Z. Dudek, MD | 6 | 2021-01-11 | 2023-11-22 |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) Alectinib, Entrectinib, Vemurafenib - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Genentech, Inc. | 99 | 2020-11-06 | 2026-11-10 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation Osimertinib, Alectinib 150 MG, Crizotinib 250 MG - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 6000 | 2020-04-16 | 2024-10-22 |
| Genetic Testing in Guiding Treatment for Patients With Brain Metastases Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib - CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 50 | 2019-10-17 | 2026-10-30 |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Alectinib, Vismodegib, Ipatasertib - Cancer of Unknown Primary Site | Phase 2 | Completed | Hoffmann-La Roche | 529 | 2018-07-10 | 2025-11-19 |
| A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) Alectinib, Atezolizumab, Pemetrexed - Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Active not recruiting | Hoffmann-La Roche | 1000 | 2017-09-22 | 2026-09-03 |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options Entrectinib - Solid Tumors, CNS Tumors | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 69 | 2016-05-03 | 2026-09-23 |
Showing 20 of 22. Sign in to see all of them.
Brain Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Glioma (3) · Hematologic Neoplasms (3) · Melanoma (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Breast Neoplasms (2) · Central Nervous System Neoplasms (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Salivary Gland Neoplasms (2) · Sarcoma (2) · Thyroid Cancer, Papillary (2)
Hoffmann-La Roche (5) · Cancer Research UK (2) · Genentech, Inc. (2) · St. Jude Children's Research Hospital (2) · Alliance for Clinical Trials in Oncology (1) · Arkadiusz Z. Dudek, MD (1) · Fondazione per la Medicina Personalizzata (1) · Helsinki University Central Hospital (1) · Hunan Province Tumor Hospital (1) · Jules Bordet Institute (1) · Oslo University Hospital (1) · Peking University Shenzhen Hospital (1) · The Netherlands Cancer Institute (1) · University of California, San Francisco (1) · West China Hospital (1)
United States (11) · China (6) · France (6) · Italy (6) · United Kingdom (6) · Germany (5) · Spain (5) · Australia (4) · Belgium (4) · Brazil (4) · Hong Kong (4) · Japan (4) · Poland (4) · South Korea (4) · Canada (3)
Matthew Krebs, Dr (2) · Adil Daud (1) · Aditi Bagchi, M.D., Ph.D. (1) · Andrea Botticelli (1) · Arkadiusz Dudek, MD, PhD (1) · Daniel Moreira, MD, MEd (1) · E.E. Voest, prof. (1) · Katriina Jalkanen, MD, PhD (1) · Paolo Marchetti (1) · Philippe Aftimos, MD (1) · Priscilla Brastianos, MD (1) · Yongchang Zhang, MD (1) · Zhihui Li, Professor (1)
PMID 40086048, PMID 31838007, PMID 41213248, PMID 29118225, PMID 31838015, PMID 32479604, PMID 33646820, PMID 34427452, PMID 34924145, PMID 35086719, PMID 35119530, PMID 35395680, PMID 35568909, PMID 35598186, PMID 35695563, PMID 35995953, PMID 36870947, PMID 36924196, PMID 37424386, PMID 37738028, PMID 38190582, PMID 38630551, PMID 38848521, PMID 38898120, PMID 39096924, PMID 39549678, PMID 40304938, PMID 40341199, PMID 40525978, PMID 41023484, PMID 41392942, PMID 41963505, PMID 41986720, PMID 42691436
2017 (2), 2023 (2), 2015 (1), 2018 (1), U10CA180821 (1)